RedHill Biopharma Ltd.
opaganib
neuroblastoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews opaganib for neuroblastoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 13h ago
“New preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, showed positive effects of opaganib as a potential add-on therapy in models of neuroblastoma and triple-negative breast cancer (TNBC”